Talphera (TLPH) Competitors $0.40 -0.02 (-3.73%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$0.41 +0.01 (+1.89%) As of 08/1/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. AKTX, MAAQ, XLO, MDCX, DYAI, SNYR, ESLA, RANI, BDRX, and SLGLShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Xilio Therapeutics (XLO), Medicus Pharma (MDCX), Dyadic International (DYAI), Synergy CHC (SNYR), Estrella Immunopharma (ESLA), Rani Therapeutics (RANI), Biodexa Pharmaceuticals (BDRX), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Its Competitors Akari Therapeutics Mana Capital Acquisition Xilio Therapeutics Medicus Pharma Dyadic International Synergy CHC Estrella Immunopharma Rani Therapeutics Biodexa Pharmaceuticals Sol-Gel Technologies Akari Therapeutics (NASDAQ:AKTX) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation. Does the media favor AKTX or TLPH? In the previous week, Akari Therapeutics and Akari Therapeutics both had 1 articles in the media. Akari Therapeutics' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score. Company Overall Sentiment Akari Therapeutics Neutral Talphera Neutral Do insiders & institutionals have more ownership in AKTX or TLPH? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 38.1% of Akari Therapeutics shares are owned by company insiders. Comparatively, 3.2% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer AKTX or TLPH? Akari Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 395.05%. Talphera has a consensus price target of $5.00, indicating a potential upside of 1,142.54%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Is AKTX or TLPH more profitable? Talphera's return on equity of -130.28% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A -213.59% -65.60% Talphera N/A -130.28%-59.25% Which has more risk and volatility, AKTX or TLPH? Akari Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Talphera has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Which has higher valuation & earnings, AKTX or TLPH? Talphera has higher revenue and earnings than Akari Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$19.79MN/AN/ATalphera$650K12.69-$13M-$0.45-0.89 SummaryTalphera beats Akari Therapeutics on 9 of the 11 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.57M$2.46B$5.48B$9.52BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-0.898.9728.6723.80Price / Sales12.69437.63373.5466.64Price / CashN/A157.7635.4557.96Price / Book0.864.838.275.55Net Income-$13M$31.62M$3.24B$259.03M7 Day Performance-4.89%-5.28%-3.69%-4.59%1 Month Performance-10.78%4.38%4.33%4.46%1 Year Performance-55.29%-2.49%25.95%18.03% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.0565 of 5 stars$0.40-3.7%$5.00+1,142.5%-56.9%$8.57M$650K-0.8919Short Interest ↑AKTXAkari Therapeutics2.6588 of 5 stars$1.11-1.8%$5.00+350.5%-73.1%$35.72MN/A0.009MAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+875.0%$35.65MN/A0.001XLOXilio Therapeutics3.2315 of 5 stars$0.68-0.3%$4.00+488.2%-31.6%$35.21M$6.34M-0.8170News CoverageMDCXMedicus Pharma2.4541 of 5 stars$2.59+6.1%$23.50+807.3%N/A$35.15MN/A-2.23N/AUpcoming EarningsDYAIDyadic International2.0793 of 5 stars$1.15+3.2%$6.00+424.0%-25.6%$34.45M$3.49M-5.727News CoveragePositive NewsSNYRSynergy CHC3.8798 of 5 stars$3.68-1.1%$10.00+171.7%+3,260.0%$33.82M$34.83M0.0040Trending NewsESLAEstrella Immunopharma2.941 of 5 stars$0.92-0.5%$16.00+1,648.6%-51.2%$33.10MN/A-3.52N/ARANIRani Therapeutics1.757 of 5 stars$0.52-5.1%$7.33+1,302.2%-80.6%$33.06M$1.03M-0.53110Upcoming EarningsShort Interest ↑BDRXBiodexa Pharmaceuticals0.1034 of 5 stars$0.88-0.6%N/AN/A$31.98MN/A0.0020News CoverageAnalyst DowngradeShort Interest ↑Gap DownSLGLSol-Gel Technologies1.7896 of 5 stars$11.45-4.7%$40.00+249.3%+209.5%$31.95M$11.54M-2.4450Gap Down Related Companies and Tools Related Companies Akari Therapeutics Alternatives Mana Capital Acquisition Alternatives Xilio Therapeutics Alternatives Medicus Pharma Alternatives Dyadic International Alternatives Synergy CHC Alternatives Estrella Immunopharma Alternatives Rani Therapeutics Alternatives Biodexa Pharmaceuticals Alternatives Sol-Gel Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
